The percentages of participants who experienced AE leading to treatment discontinuation as well as of those who experienced gastrointestinal AE with oral semaglutide 50 mg (Tables 2 and 3) were similar to those observed with subcutaneous semaglutide 2.4 mg (in STEP-1 and STEP-2 trials 67% discontinued treatment due to AE, 3444% experienced nausea, 2132% diarrhoea and 2225% vomiting) [11, 29]
The same study showed that patients taking higher doses and remaining adherent achieved weight loss comparable to clinical trials
For many people, this is a small price to pay for avoiding needles entirely
Many patients with commercial insurance can access GLP-1 medications for between \$150\$300 per month out-of-pocket, according to multiple clinics and real-world testimonials
Hims & Hers' weight loss business continues to be a major focus for the company, and that segment is on pace to bring in $725 million in revenue in 2025, Yemi Okupe, Hims & Hers' chief financial officer, said during the Q3 call with investors in early November
J Biol Chem 1923;58:337-46
